	medRxiv preprint doi: https://doi.org/10.1101/2022.05.23.22275201; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
	All rights reserved. No reuse allowed without permission. Qureshi et al Biomarker Analytical Validation Manuscript MedRxiv
1	Analytical validation of a multi-protein, serum-based assay for disease activity
2	assessments in multiple sclerosis
2	
3	
4	Ferhan Qureshi, ¹ * Wayne Hu, ¹ * Louisa Loh, ¹ Hemali Patel, ¹ Maria DeGuzman, ¹
5	Michael Becich, ^{1†} Fatima Rubio da Costa, ^{1†} Victor Gehman, ^{1†} Fujun Zhang, ^{1†}
6	John Foley, ² Tanuja Chitnis ³
7	¹ Octave Bioscience, Inc., Menlo Park, CA, USA
8	² Rocky Mountain Multiple Sclerosis Clinic, Salt Lake City, UT, USA
9	³ Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
10	*These authors contributed equally to this work
11	[†] Employee of Octave Bioscience, Inc., at the time the study was completed
12	
13	Correspondence
14	Ferhan Qureshi
15	1440 Obrien Drive, Suite B
16	Menlo Park, CA 94025, USA
17	Email: fqureshi@octavebio.com
18	Phone: 650-224-3072
19	Fax: 650-479-8876
20	
21	Abbreviations:
22	%CV, percent coefficient of variation; APLP1, amyloid beta precursor-like protein 1;
23	CCL20, C-C motif chemokine ligand 20; CD6, cluster of differentiation 6; CDCP1,
24	CUB domain-containing protein 1; Cmax, maximum concentration; CNS, central
25	nervous system, CNTN2, contactin 2; COL4A1, collagen type IV alpha-1; conc,
26	concentration; CSF, cerebrospinal fluid; CXCL9, chemokine (C-X-C motif) ligand 9
27	(MIG); CXCL13, chemokine (C-X-C motif) ligand 13; DMT, disease-modifying
28	therapy; DNA, deoxyribonucleic acid; FLRT2, fibronectin leucine-rich repeat
29	transmembrane protein; Gd+, gadolinium positive; GFAP, glial fibrillary acidic protein;

- 30 GH, growth hormone; HAMA, human anti-mouse antibodies; HCI, hydrochloride; IL-
- 31 12β, interleukin-12 subunit beta; LLOQ, lower limit of quantitation; LOQ, limit of
- 32 quantitationin makes monoclonal antibody maximum in Minneminimum in Minneminimum in Minneminimum in Minner practice.

	medRxiv preprint doi: https://doi.org/10.11 preprint (which was not certified by pee	101/2022.05.23.22275201; this version posted January 31, 2023. The review) is the author/funder, who has granted medRxiv a license to perpetuity.	e copyright holder for this o display the preprint in							
	Qureshi et al Bioma	rker Analytical Validation Manuscript	MedRxiv							
33	myelin oligodendrocyte gl	ycoprotein; MRI, magnetic resonance imagin	g; MS, multiple							
34	sclerosis; MSDA, Multiple Sclerosis Disease Activity; Na, sodium; NfL, neurofilament									
35	light chain; OPG, osteoprotegerin; OPN, osteopontin; PCR, polymerase chain									
36	reaction; PEA, Proximity Extension Assay; PRTG, protogenin; qPCR, quantitative									
37	polymerase chain reaction	n; R ² , coefficient of determination; RA, rheum	atoid arthritis;							
38	RF, rheumatoid factor; SI	D, standard deviation; SERPINA9, serpin fam	ily A member							
39	9; TNFRSF10A, tumor ne	crosis factor receptor superfamily member 10)A (TRAIL-R1);							
40	TNFSF13B, tumor necros	sis factor superfamily member 13B (BAFF); U	LOQ, upper							
41	limit of quantitation; VCA	N, versican core protein								
42										
43	Key words:									
44	Analytical characterization	n, analytical validation, biomarker, multiple sc	lerosis,							
45	proximity extension assay	/								
46										
47	Total word count:	3964 (5000 maximum)								
48	Running head:	Analytical Validation of a Serum-Based Ass	ay for Disease							
49		Activity Assessments in Multiple Sclerosis								
50	Previous presentation:	Part of this work, namely analytical validatio	n of the							
51		individual biomarkers in the MSDA Test, wa	s previously							
52		presented at the ACTRIMS 2021 Forum, Vir	tual (February							
53		25–27, 2021) and analytical validation of the	Disease							
54		Activity Score and 4 Disease Pathway Score	es, was							
55		previously presented at the ACTRIMS 2022	Forum, West							
56		Palm Beach, Florida (February 24–26, 2022	<u>'</u>)							

Biomarker Analytical Validation Manuscript

MedRxiv

57 **Clinical relevance**

Qureshi et al

Multiple sclerosis (MS) is a chronic, neurodegenerative, immune-mediated disease of 58 59 the CNS. MS has a complex disease course with variable clinical outcomes. Although 60 many treatments are effective in early stages of the relapsing/remitting form of the 61 disease, early diagnosis and treatment are critical to managing disease activity and slowing disease progression. One of the major areas of focus in MS research is the 62 63 identification of biomarkers in biological fluids, such as cerebrospinal fluid or blood, to 64 track pathogenesis, disease activity, and disease progression, which can lead to 65 individualized disease management and improved quality of care. Currently, there 66 are no validated clinical tests that leverage multiple blood biomarkers to track disease activity or progression in patients with MS. Herein, we describe the analytical 67 68 characterization and validation of a multi-protein, serum-based assay panel 69 developed using Olink[®] PEA methodology. We demonstrate the extensive 70 characterization of this multi-protein, serum-based assay and establish its accuracy, 71 precision, sensitivity, and robustness. This report will be followed by a 72 complementary clinical validation study investigating the correlation between the 73 proteomic assay results and relevant clinical and radiographic endpoints for patients 74 with MS.

perpetuity. All rights reserved. No reuse allowed without permission.

All rights reserved. No reuse allowed without permiss Biomarker Analytical Validation Manuscript

MedRxiv

75 Abstract

- 76 **Purpose:** To characterize and analytically validate the MSDA Test, a multi-protein,
- ⁷⁷ serum-based biomarker assay developed using Olink[®] PEA methodology.
- 78 **Experimental design:** Two lots of the MSDA Test panel were manufactured and
- ⁷⁹ subjected to a comprehensive analytical characterization and validation protocol to
- 80 detect biomarkers present in the serum of patients with MS. Biomarker
- 81 concentrations were incorporated into a final algorithm used for calculating four
- 82 Disease Pathway scores (Immunomodulation, Neuroinflammation, Myelin Biology,
- and Neuroaxonal Integrity) and an overall Disease Activity score.
- 84 **Results:** Analytical characterization demonstrated that the multi-protein panel
- satisfied the criteria necessary for a fit-for-purpose validation considering the assay's
- 86 intended clinical use. This panel met acceptability criteria for 18 biomarkers included
- in the final algorithm out of 21 biomarkers evaluated. VCAN was omitted based on
- 88 factors outside of analytical validation; COL4A1 and GH were excluded based on
- 89 imprecision and diurnal variability, respectively. Performance of the four Disease
- 90 Pathway and overall Disease Activity scores met the established acceptability
- 91 criteria.
- 92 **Conclusions and clinical relevance:** Analytical validation of this multi-protein,

93 serum-based assay is the first step in establishing its potential utility as a quantitative,

- 94 minimally invasive, and scalable biomarker panel to enhance the standard of care for
- 95 patients with MS.

perpetuity. All rights reserved. No reuse allowed without permission.

Qureshi et al Biomarker

Biomarker Analytical Validation Manuscript

MedRxiv

96 What is known and what is new in your work?

97 What's known

- Multiple sclerosis (MS) has a complex disease course with variable clinical
- 99 outcomes; early diagnosis and treatment are critical to management of MS.
- One key focus in MS research is the identification of biomarkers in biological
- 101 fluids, such as cerebrospinal fluid or blood, to track pathogenesis, disease activity,
- 102 and disease progression, which may lead to individualized disease management
- 103 and improved quality of care.
- There currently are no validated clinical tests that leverage multiple blood
- 105 biomarkers to track disease activity or progression in patients with MS.

106 What's new

- 107 The MS Disease Activity (MSDA) Test is a multi-protein, serum-based biomarker
- 108 assay designed to quantitatively measure disease activity using the protein levels
- 109 of biomarkers present in the serum of patients with MS.
- In this study, we evaluated 21 biomarkers, 18 of which were selected for inclusion
- 111 in the MSDA Test, and extensively characterized the MSDA Test (individual
- biomarkers and algorithmic scores) by establishing the accuracy, precision,
- 113 sensitivity, and robustness of the assay.
- This study serves as a critical first step in the validation of this multi-protein,
- serum-based assay, which will be a quantitative, minimally invasive, and scalable
- 116 tool to improve MS disease management.

Qureshi et al

Biomarker Analytical Validation Manuscript

MedRxiv

117 **1 INTRODUCTION**

118 Multiple sclerosis (MS) is a chronic, neurodegenerative, immune-mediated disease of 119 the CNS, characterized by inflammatory demyelination and neuronal damage.[1,2] 120 MS has a complex disease course with variable symptoms or manifestations that can 121 range from mild and self-limiting to severe.[1] The clinical course, after the first 122 clinical manifestation of the disease, or clinically isolated syndrome, can vary.[3] The damage caused by MS typically leads to relapses, or acute attack of symptoms, 123 124 followed by progressive disease.[4] Most treatments are effective in early stages of 125 the relapsing/remitting form of the disease; [4,5] however, a delay in treatment can lead to irreversible damage.[6] Studies show that the extent of remyelination in early 126 MS is greater than in chronic MS.[7] Clinical studies are underway to explore 127 128 treatments targeting remyelination, which may slow or offset disease progression.[8] 129 The McDonald Criteria, designed to improve the accuracy of MS diagnosis, 130 established the use of MRI to show the accrual of lesions over time and space.[9] 131 The revised McDonald Criteria substituted CSF oligoclonal immunoglobulin G bands 132 for the second clinical/MRI finding.[10] Nonetheless, use of any of these 133 assessments do not always accurately predict disease activity, course, progression, 134 recurrence, or response to treatment.[11-13] As such, there is an unmet clinical need 135 for objective and quantitative measures that can accurately diagnose MS, monitor 136 disease activity, and promote individualized disease management.[13,14] 137 One major area of focus in MS is the identification of biomarkers in biological fluids, such as CSF or blood, to track pathogenesis, disease activity, and 138 139 progression.[14,15] One of the key therapeutic strategies in MS is to reduce relapse, 140 lesions, and brain atrophy at all disease stages.[4] As a result, new biomarkers for 141 early MS diagnosis and disease activity monitoring can lead to prevention of disease

medRxiv preprint doi: https://doi.org/10.1101/2022.05.23.22275201; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission. Qureshi et al Biomarker Analytical Validation Manuscript MedRxiv 142 progression, potentially reducing the patient's level of disease worsening.[14] The dynamic range of proteins in CSF presents challenges when differentiating small 143 144 disease-specific changes from inherent inter-individual differences, especially as it 145 relates to methodological variations.[16,17] CSF collection also requires invasive procedures, such as lumbar puncture. On the other hand, blood-based collection of 146 147 biomarkers allows for safe, quick, and easy collection.[14] With these considerations, 148 detection of biomarkers in blood is a viable and attractive option for the accurate 149 diagnosis and assessment of disease activity and progression in MS. However, there 150 currently are no validated clinical tests that leverage multiple blood biomarkers to 151 track disease activity or progression in patients with MS.[18] 152 Development of multi-protein assays can be challenging. Each protein 153 biomarker requires specific conditions and methodologies for optimal quantification. 154 The optimal multi-protein assay should be designed so that stability and integrity of all biomarker proteins are maintained and optimized to eliminate cross-reactivity.[19] 155 156 Larger scale, proteomic techniques allow higher throughput of samples and more 157 timely readout. However, maintaining robustness, repeatability, and sensitivity is 158 challenging, yet critical, to the validation of a multi-protein biomarker panel.[20] 159 Analysis of multiple proteins may more accurately represent the various 160 pathways, processes, and cell types involved in complex disease states and has the 161 potential to deliver more personalized medicine for MS.[20-23] Single proteins may 162 not perform well alone as diagnostic or prognostic markers. However, as part of a 163 multi-protein assay, they may contribute to a clinically useful model when combined 164 with other proteins and biomarkers.[21] Therefore, multi-protein assay platforms have 165 been characterized and validated for complex disease states.[19,21,22,24] 166 The MSDA Test is a multi-protein, serum-based biomarker assay designed to 167 guantitatively measure disease activity using the protein levels of biomarkers present

perpetuity. All rights reserved. No reuse allowed without permission. Biomarker Analytical Validation Manuscript

MedRxiv

168 in the serum of patients with MS. Our custom multi-protein assay panel was

169 developed using the Olink[®] PEA (Olink Proteomics, Uppsala, Sweden) methodology

170 described previously (Figure S1).[19] Herein, we describe the comprehensive

171 analytical characterization and validation of the MSDA Test to satisfy the criteria

172 necessary for a fit-for-purpose validation considering the assay's intended clinical

173 use.

174

175 **2 EXPERIMENTAL SECTION**

176 2.1 Assay development

Qureshi et al

Twenty-one biomarkers were selected for inclusion in the custom assay panel based 177 178 on statistical associations with clinical and radiographic endpoints as demonstrated in 179 feasibility studies for which >1400 proteins were screened using 2 immunoassay 180 platforms (Table S1). These feasibility studies investigated biomarker associations 181 (single-protein and multi-protein) in both cross-sectional and longitudinal samples relative to several radiographic and clinical MS endpoints, including clinically defined 182 183 relapse versus remission (exacerbation versus guiescence), the presence and count 184 of gadolinium-enhanced lesions on a matched MRI, annualized relapse rate, and 185 Expanded Disability Status Scale. From these studies, the custom panel of 21 186 proteins was selected with a primary focus on the detection and prediction of disease 187 activity status. The 21 proteins were chosen based on their statistical significance 188 relative to the aforementioned endpoints and with the intent to comprehensively 189 survey the biological pathways, mechanisms, and cell types associated with MS 190 pathophysiology as determined via literature review, protein-protein interaction 191 modeling, gene set enrichment, and spatial expression profiling.[25] Dynamic range 192 of the individual protein assays was considered, as well as the intent to develop a

perpetuity. All rights reserved. No reuse allowed without permission.

Qureshi et alBiomarker Analytical Validation ManuscriptMedRxiv193single multi-protein immunoassay panel for which each protein could be measured in194an undiluted serum sample. The MSDA Test algorithm consisting of 18 biomarkers195included in the panel was finalized in a subsequent clinical validation study for which196independent sample sets were analyzed. The final model was trained and validated197relative to the presence and count of gadolinium-enhanced lesions.

Serum pools (*n*=4) were included on all runs during assay discovery and development. They were procured in large volumes, aliquoted, stored at -65°C, and run in triplicate. Serum pools were used solely to assess the analytical performance of the assays and served as process controls to determine acceptability of future analytical runs. The SD of repeated measurements was applied to the expected concentrations. Two assay kit lots of the panel were manufactured for which critical reagents were varied to the extent possible.

205 2.2 Description of the two-layer stacked classifier algorithm for determination
206 of the overall Disease Activity score

207 A two-layer, L2-penalized logistic regression stacked classifier model was developed 208 and clinically validated in a separate study that optimized the model's performance to 209 classify serum samples based on the presence of gadolinium-enhancing lesions (0 210 lesions or ≥1 lesions) on an MRI administered within 60 days of blood draw.[26] In 211 the first layer of the model, individual protein concentrations in log₁₀ which were 212 demographically corrected for age and sex and LOQ-imputed (referred to as adjusted 213 concentrations) were used as inputs into the four Disease Pathway models 214 (Immunomodulation, Neuroinflammation, Myelin Biology, and Neuroaxonal Integrity). 215 The second layer of the model used the adjusted protein concentrations and the 216 output (eg, the probability) of the Disease Pathway models as meta features to 217 calculate an overall Disease Activity score (File S1, Supporting Information).

All rights reserved. No reuse allowed without permission.Qureshi et alBiomarker Analytical Validation ManuscriptMedRxiv

218 Thresholds were established, which corresponded to low (1.0-4.0), moderate (4.5-

- 219 7.0), and high (7.5–10.0) Disease Activity scores. Analytical characterization and
- 220 validation of the individual biomarkers were factors used to determine inclusion of
- those biomarkers in the algorithm.

222 **2.3 Incurred sample reanalysis**

223 Incurred sample reanalysis was performed to characterize precision and robustness

for the individual biomarkers and the Disease Activity and Disease Pathway scores.

225 Forty-eight individual samples from patients with MS were repeatedly analyzed

across 10 plates over ≥5 days with varied equipment, reagents, location, and

- 227 personnel. Acceptability criteria for individual biomarkers was an average %CV
- $228 \leq 20\%$, and average SD at all established Disease Activity score levels of ≤ 1.0 units.
- 229 The 48 samples broadly represented the expected range of biomarker values and
- 230 Disease Activity scores in the real-world MS population.

231 **2.4 Assay accuracy, precision, and sensitivity**

232 Accuracy for each analyte was determined by mixing serum samples at different 233 ratios and evaluating the percent recovery of the observed concentration relative to 234 the expected concentration. Sample mixing enabled the accuracy assessment to be 235 performed using endogenous protein versus a recombinant protein source. Expected 236 concentrations were calculated by applying the targeted ratios of unmixed samples. 237 The ratios of sample mixtures with two samples were 25%:75%, 50%:50%, and 238 75%:25%. The ratios of sample blends for mixtures with four samples were 239 25%:25%:25% and 40%:10%:40%:10%. Additionally, accuracy was also evaluated for the Disease Pathway and Disease Activity algorithms by correlating 240 241 observed scores with expected scores using the same sample mixtures created for 242 the individual analyte assessments.

medRxiv preprint doi: https://doi.org/10.1101/2022.05.23.22275201; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

MedRxiv

Qureshi et al **Biomarker Analytical Validation Manuscript** 243 Intra- and inter-assay precision was measured for each analyte. The %CV was determined using serum pools enabling the assessment to be performed using 244 245 endogenous protein. Serum pools were manufactured to represent patients with 246 shorter and longer MS disease duration, those with inflammatory disease 247 (rheumatoid arthritis), and one healthy control. Acceptability criteria for intra- and 248 inter-assay precision was established as %CV ≤15% and ≤20%, respectively. 249 Sensitivity was defined as the assay's ability to accurately and precisely detect 250 low concentrations of a given substance in biological specimens. To establish the 251 ULOQ and LLOQ, a LOQ panel was manufactured during assay development. For each analyte, four levels were targeted near the anticipated upper limit (ULOQ 1-4) 252 253 and four levels were targeted near the anticipated lower limit (LLOQ 5-8). The 254 targeted concentrations were based on expected real-world MS patient sample 255 distributions, the shape of the standard curve, and location of asymptotes. The LOQ 256 panel was run in triplicate over two lots (≥ 5 runs per lot) and fit to the standard curve. 257 Accuracy, defined as 80–120% recovery relative to the expected concentration and 258 precision (inter-assay %CV ≤20%), were used to establish the acceptability criteria 259 and determine the LLOQ and ULOQ of each analyte. Additionally, individual LOQs were assessed and established separately for each kit lot. The most conservative 260 261 LOQ levels with acceptable accuracy and precision parameters for both lots were 262 used to establish the final LLOQ and ULOQ.

263 Undiluted serum samples were run in the MSDA Test and as a result, no dilution factor was accounted for in the sensitivity analysis. Therefore, the LLOQ and 264 265 ULOQ define both the analytical measurement range and the reportable range of the 266 assay. Serum samples that recovered either above the ULOQ or below the LLOQ were reported at the established LOQ concentration (referred to as LOQ imputation). 267 MS serum samples were used to establish MS reference ranges for each biomarker. 268

medRxiv preprint doi: https://doi.org/10.1101/2022.05.23.22275201; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in pr

perpetuity. All rights reserved. No reuse allowed without permission.

Qureshi et al **Biomarker Analytical Validation Manuscript** MedRxiv 269 A diverse set of patient samples were used throughout the assay development process and for the analytical validation studies. A total of 1645 samples from nine 270 271 deeply phenotyped cohorts were analyzed primarily for evaluating associations of 272 biomarkers with MS disease activity and disease progression endpoints. Additional 273 samples from both patients with MS and other disease states were procured for 274 specific analytical characterization experiments. The 1645 samples that were 275 analyzed for the associations of biomarkers with MS endpoints were combined in the 276 subsequent analysis to establish MS reference ranges. These samples were 277 collected both retrospectively and prospectively from nine US and international sites and broadly represent the real-world MS population. The mean ± SD age of these 278 279 patients at the time of the blood draw was 40.85 ± 11.0 years, with a mean \pm SD 280 disease duration of 8.39 ± 8.0 years: 72.8% of the patients were female. For race, the top 3 categories were White (81.4%), unknown/not reported (13.5%), and 281 Black/African American (2.7%). The primary endpoint used to train the finalized 282 283 MSDA Test algorithm was the presence and count of gadolinium-enhancing lesions 284 on an MRI administered within close proximity to the blood draw. For the 1645 patient 285 samples, 1326 had available gadolinium-positive (Gd+) lesion counts and 53.0% of the patient samples had ≥1 Gd+ lesion. The linear interpolation method was used to 286 287 establish the 95% interval (2.5th and 97.5th percentiles).[27] The percentile relative 288 to these reference ranges are presented with their protein concentrations.

289 **2.5 Assay interference**

Assay interference was defined as the effect of a substance present in the sample altering the correct value of the result or the recovery of samples in the assay. Since patients with MS may be treated with a variety of drugs, potential interference of drugs was tested to determine if their presence would affect measurement of the individual protein biomarkers. Concentrations of common prescriptions, over-the-

perpetuity. All rights reserved. No reuse allowed without permission.

MedRxiv

295 counter drugs, common MS drugs, and DMTs were spiked into serum samples

296 (**Table S2**). Concentrations of common prescription and over-the-counter drugs were

Biomarker Analytical Validation Manuscript

- 297 determined by Sun Diagnostics (New Gloucester, ME, USA) using a commercially
- available test kit. DMTs were targeted at two times C_{max} from pharmacokinetic
- studies, or the highest possible concentration allowable for spiking with the procured
- 300 interferent stock. Finally, a universal mAb standard was tested at two concentrations
- 301 (424 and 7.93 µg/mL) to cover the two times C_{max} of several mAb DMTs.
- 302 Endogenous substances (hemoglobin, bilirubin, and lipids) and heterophilic
- 303 antibodies (RF and HAMA) were also measured. For most interferent substances, the
- 304 acceptability threshold, or median recovery, for the interference assessment was
- 305 established as 80–120% relative to a corresponding spike control, except for HAMA
- 306 for which percent recovery of sample mixtures was evaluated (File S2, Supporting
- 307 Information).

Qureshi et al

308 **2.6 Diurnal variability**

- 309 Patient serum samples were collected at days 1–5 and day 12 to characterize
- biomarker level fluctuations. For each of the six time points per patient, the %CV and
- 311 the percentage difference of the observed protein concentration relative to the
- 312 average concentration at all time points were calculated.

313 **2.7 Sample stability**

In an initial experiment, stability studies for four serum samples were performed to determine the effect that storage and processing conditions can have in a clinical setting. Stability was assessed at the following four temperatures: -65° C or below (-80° C), -10° C or below (-20° C), $2-8^{\circ}$ C (4° C), and room temperature ($18-25^{\circ}$ C) at the following time points: 4 hours (for 4°C and room temperature) and days 1, 3, 7, 14, and 28 (for -20° C, 4°C, and room temperature). The results from -20° C, 4°C,

All rights reserved. No reuse allowed without permiss Biomarker Analytical Validation Manuscript

MedRxiv

320 and room temperature were compared with the control storage condition (-80°C). In

321 a follow-up study, the stability of storage of 14 samples was evaluated at 4°C at days

322 1–3 and 7 compared with a control storage condition (-80°C) to establish the

323 duration of time samples that can be stored at 4°C. Five freeze-thaw cycles,

324 performed at -65°C or below, were also evaluated using four MS serum samples

325 compared with fresh samples.

Qureshi et al

326

327 3 RESULTS AND DISCUSSION

328 **3.1 Analytical characterization and validation**

329 Experiments were performed between July 2020 and July 2021. Fifty-one plates were

run (40 and 11 plates using the first and second lots of manufactured kits,

331 respectively).

Based on the analytical validation and characterization of individual

biomarkers described below, the 18 out of 21 biomarkers that were included in the

algorithm were determined to have acceptable analytical performance. GH and

335 COL4A1 were excluded from the algorithm based on the analytical characterization

336 studies described below. VCAN was not incorporated into the final algorithm due to

337 biostatistical factors unrelated to analytical performance.

338 **3.2 Incurred sample reanalysis**

All individual biomarkers were determined to have a mean %CV <20% and met

340 established acceptability criteria (**Figure 1A**). The Disease Activity score and the four

341 Disease Pathway scores demonstrated reproducible results throughout the range of

- scores (**Figures 1B–1F**). For the Disease Activity score, the average SD across 48
- 343 samples was observed to be 0.3 score units, which is less than one interval (0.5) on
- 344 the reportable scale, and as a result, met acceptability criteria. Additionally, incurred

All rights reserved. No reuse allowed without permiss Biomarker Analytical Validation Manuscript

MedRxiv

345 sample reanalysis showed robustness and equivalency of the assay between lots

and laboratories, with the exception of COL4A1 (**Table S3**).

347 **3.3 Assay accuracy, precision, and sensitivity**

Qureshi et al

348 Samples for the accuracy assessment were selected from an internal MS cohort

349 (*n*=64) to target both high and low concentrations for the individual biomarkers

350 relative to the MS population. Twenty mixed samples from four selected samples

351 were analyzed for each biomarker. Minimum percent recovery for each biomarker

ranged from 78% to 89%; the maximum percent recovery for each biomarker ranged

353 from 99% to 124%. The median percent recovery ranged from 91% to 100% (Figure

354 **2A**). Additionally, the Disease Pathway and overall Disease Activity scores were

355 calculated for both observed and expected concentrations of the various sample

356 mixtures. The observed calculated scores correlated with the expected scores; R²

 ≥ 0.85 was established as the acceptability criteria (**Figures 2B–2F**).

Twelve replicates per serum pool were analyzed on a single plate for the intra-358 359 assay precision assessment: <51 values per serum pool were analyzed across 51 360 plates spanning 2 lots of reagent kits. The intra- and inter-assay precision satisfied 361 the criteria for meeting the precision parameter with most analytes passing the 362 established criteria. Of note, COL4A1 was found to have inferior inter- and intra-363 assay precision that ranged from 7% to 47% and 15% to 59%, respectively. Based 364 on these findings, COL4A1 was removed from consideration for inclusion in the algorithm. MS serum samples (*N*=1645) were analyzed during the assay 365 366 development and validation process and used to establish the MS reference ranges for each analyte. Sensitivity analysis demonstrated that the LLOQ and ULOQ of each 367 368 analyte met the sensitivity requirements established for the assay. The maximum percentage of samples requiring imputation at any LOQ was 1.8% (for NfL at LLOQ) 369 370 (Table 1).

perpetuity. All rights reserved. No reuse allowed without permission.

Qureshi et al Biomarker Analytical Validation Manuscript

MedRxiv

371 3.3 Assay interference

- Most biomarker interactions with interferent combinations, such as common MS 372 373 drugs, DMTs, and mAbs produced a median recovery that ranged from 80% to 120% 374 (Figure 3). A lower percentage recovery was observed for two biomarkers, COL4A1 375 and CCL20, demonstrating a potential alteration in the presence of the sample for 376 individual drugs. COL4A1 produced a low percent recovery for several drugs that 377 ranged from 71% to 79%, which was likely an artifact of established assay 378 imprecision (Figure 3 and Figure S2). For CCL20, cefoxitin spiked at 660 mg/dL 379 resulted in a median percent recovery of 77% (Figure S2). Additional assay interferents are shown in Figures S2 (common drugs) and S3 (routine endogenous 380
- interferents and heterophilic antibodies).

382 3.4 Diurnal variability

383 Diurnal variation was evaluated in eight patients over six time points (Figure S4).

384 Mean and median percent differences for each biomarker and patient were observed

to be within ±20%; mean and median %CV was found to be <30% for 19 of the 21

biomarkers (**Table 2**). Of note, there were some individual samples that were outside

of the acceptable range (±30%; data not shown). In addition, mean and median

diurnal variability \geq 30% was observed for COL4A1, which may have been due to the

imprecision of the assay to detect this biomarker. GH was also found to be more

390 variable compared with the other biomarkers, which is not surprising, as GH has

- been previously reported to have a high degree of ultradian and diurnal variability.[28]
- 392 For this reason, GH was removed from consideration for inclusion in the algorithm.

393 **3.5 Sample stability**

In the initial stability study, all biomarkers were stable for up to 1 day at room

temperature and at 4°C, and for 28 days at -20°C. For those samples stored at room

medRxiv preprint doi: https://doi.org/10.1101/2022.05.23.22275201; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity.

	Qureshi et al	All rights reserved. No Biomarker Analytical	reuse allowed without permise Validation Manuscript	sion.	MedRxiv
396	temperature, CXC	L13, IL-12β, and TN	FSF13B decreased	beyond −20% at 3	3 days.
397	During a follow-up	study, all biomarke	s were found to mee	et acceptability crit	eria
398	when stored at 4°	C, and consistent wi	h the initial study as	well as the contro	ıl
399	condition (-80°C)	at follow-up (Table \$	64). In a study to exa	amine the stability	of
400	samples after free	ze-thaw, most biom	arkers met acceptabi	lity criteria when	
401	compared with fre	sh sample. Of note,	GFAP concentration	s decreased beyo	nd −20%
402	for freeze-thaw cy	cles 4 and 5 (Table	\$5). Finally, score le	vel analysis show	ed that
403	test conditions we	re within 3 SDs (±1.	score difference) fr	om the control cor	nditions
404	during the initial st	udy (Table S6) and	at follow-up (Table \$	37). From these fir	ndings,
405	we showed that bi	omarker levels were	found to be most af	fected above certa	ain
406	thresholds (room t	emperature for 24 h	ours, 4°C for 7 days,	−20°C for 28 day	s, and
407	three freeze-thaws	s). These data can b	e used to establish a	allowable sample h	nandling
408	and storage condi	tions. Beyond these	empirical estimation	s of protein stabilit	ty, it is
409	also important to r	note that statistically	meaningful associati	ions of biomarkers	s with
410	multiple MS endpo	oints were observed	using samples that h	had been stored at	t −80°C
411	for extended perio	ds of time. This sug	gests that the target	epitopes for the pr	roteins
412	that were selected	for inclusion in the	custom assay panel	and the final algor	ithm
413	were sufficiently s	table to derive clinica	ally meaningful insight	nts.	

414

415 **4 CONCLUSION**

The accuracy, precision, and reproducibility of a biomarker assay are critical to its
utility as a diagnostic and prognostic tool in the management of complex
neurodegenerative disorders such as MS. Additionally, such an assay should be
insensitive to external factors such as assay interferents and sample collection,
processing, and storage. The Clinical and Laboratory Standards Institute and the

perpetuity. All rights reserved. No reuse allowed without permission. Qureshi et al Biomarker Analytical Validation Manuscript MedRxiv 421 United States Food and Drug Administration issued guidance on the development and validation of assays for the detection of serum-based biomarkers.[27,29,30] 422 423 Parameters such as accuracy, precision, recovery, sensitivity and specificity, quality 424 control, and sample stability need to be optimized for the assay to be properly 425 validated.[27,29,30] Results from our analytical validation experiments to 426 characterize the MSDA Test support that the assay is accurate, precise, sensitive, 427 specific, and robust at determining individual biomarker levels and algorithmic scores, 428 regardless of assay interferents, and validated in terms of sample stability. Our 429 findings of high accuracy and precision for the MSDA Test assay align with those of 430 other validation studies of multi-protein assays utilizing the same.[31.32] as well as 431 alternative[21,22] platforms. 432 PEA demonstrated high sensitivity, specificity, reproducibility, and repeatability with low intra- and inter-assay variability, which has allowed for large-scale, high 433 434 throughput screening of up to 92 proteins in 96 samples simultaneously, with low 435 sample consumption and cost.[19] This platform detected novel protein biomarkers 436 and biomarker combinations for many complex disease states, such as 437 cardiovascular disease, [33-37] cancer, [32, 38-40] Alzheimer's disease, [41] and inflammatory diseases such as atopic dermatitis and lupus[42.43]: the platform has 438

also proven useful in aging research.[44] For the MSDA Test, we demonstrated that

440 a focused panel of MS biomarkers can be developed and optimized on the PEA

441 platform with absolute quantitation of the proteins to support a fit-for-purpose

442 analytical validation, thereby enabling clinical use of the assay.

Thus far, there are no validated clinical tests that leverage multiple blood biomarkers to track disease activity or progression in patients with MS. This is critical for a disease such as MS, which has a complicated clinical course varying from mild, self-limiting to severe.[1] Although MS disease prognosis is primarily based on

perpetuity.All rights reserved. No reuse allowed without permission.Qureshi et alBiomarker Analytical Validation ManuscriptMedRxiv

447 clinical evidence, such as relapse rate and disability progression, and diagnostic tests (eg, brain MRI or the presence of oligoclonal immunoglobulin G bands in the 448 449 CSF),[14] neither can consistently and accurately predict disease course, activity, or 450 prognosis.[13] Given the emphasis on early diagnosis and the efficacy of therapies to 451 treat early stages of the relapsing/remitting form of the disease, [4,5] validation of a 452 biomarker panel remains an unmet need in clinical practice, and use of this 453 biomarker tool should provide diagnostic and prognostic value for the treatment of 454 MS. This study demonstrated identification of biomarkers for this complex disease 455 using the PEA platform. With further clinical validation, this assay can potentially be used to track disease activity and progression of MS, allowing a more personalized 456 457 approach to MS treatment.

A limitation of using a multi-protein assay is that the conditions established for one biomarker are not always uniform across the full panel of biomarkers. Our findings show that the MSDA Test was optimized for assessment of 18 out of the 21 included biomarkers and the analytical validation paradigm that we described demonstrates a high level of accuracy, sensitivity, and precision with minimal crossreactivity and interference by substances commonly seen in patients with MS.

This study serves as a critical first step in the validation of a multi-protein. 464 serum-based assay. The next step in the validation of the MSDA Test is clinical 465 466 validation, which will support and confirm the association between the serum-based 467 MSDA Test and clinical and radiographic MS endpoints. Upon completion of clinical validation of the assay, the final Disease Activity and Disease Pathway algorithms will 468 469 use the ensemble of validated proteins to expand the use of the assay by evaluating 470 biomarker correlations with endpoints associated with additional MS disease 471 assessments, selection of therapy, and differential diagnosis of patients with MS. 472 Upon successful clinical validation, this MSDA Test will be a quantitative, minimally

- All rights reserved. No reuse allowed without permission.Qureshi et alBiomarker Analytical Validation ManuscriptMedRxiv
- 473 invasive, and scalable tool to improve disease management for patients with MS and
- 474 their physicians.

Qureshi et al **Biomarker Analytical Validation Manuscript**

MedRxiv

475 ACKNOWLEDGMENTS

- The authors wish to thank the following team members from Olink Proteomics 476
- (Uppsala, Sweden) who were involved in the development of the Multiple Sclerosis 477
- 478 Disease Activity Test assay: Erika Assarsson, Sandra Ohlsson, Martin Lundberg,
- Jessica Bergman, and Niklas Nordberg. All authors contributed to and approved the 479
- 480 manuscript for submission. Writing and editorial assistance were provided by Jennifer
- 481 L. Venzie, PhD, and Bu Reinen, PhD, CMPP, of The Lockwood Group (Stamford,
- CT, USA), and were funded by Octave Bioscience, Inc. 482
- 483

484 **CONFLICT OF INTEREST STATEMENT**

F. Qureshi, W. Hu, L. Loh, H. Patel and M. DeGuzman are employees of Octave 485

486 Bioscience, Inc. M. Becich, F. Rubio da Costa, V. Gehman, and F. Zhang were

employees of Octave Bioscience, Inc. at the time the study was completed. J. Foley 487

has received research support from Biogen, Novartis, Adamas, Octave Bioscience, 488

489 Inc., Genentech, and Mallinckrodt, received speakers' honoraria and acted as a

490 consultant for EMD Serono, Genzyme, Novartis, Biogen, and Genentech, and has

equity interest in Octave Bioscience Inc., and is the founder of InterPro Biosciences. 491

T. Chitnis has received compensation for consulting from Biogen. Novartis 492

Pharmaceuticals, Roche Genentech, and Sanofi Genzyme, and received research 493

support from the National Institutes of Health, National MS Society, US Department 494

495 of Defense, EMD Serono, I-Mab Biopharma, Mallinckrodt ARD, Novartis

Pharmaceuticals, Octave Bioscience, Inc., Roche Genentech, and Tiziana Life 496

497 Sciences.

Biomarker Analytical Validation Manuscript

MedRxiv

498 FUNDING

- The study was funded by Octave Bioscience, Inc. and in part by the U.S. Department 499
- 500 of Defense (W81XWH2110633 to T Chitnis).
- 501

DATA AVAILABILITY STATEMENT 502

- 503 Access to data can be provided after a research proposal is submitted to the
- 504 corresponding author and a data sharing agreement is in place.

medRxiv preprint doi: https://doi.org/10.1101/2022.05.23.22275201; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

Qureshi et al

Biomarker Analytical Validation Manuscript

MedRxiv

505 REFERENCES

506

507 [1] Compston, A., Coles, A. (2008). Multiple sclerosis. Lancet, 372, 1502-1517. 508 [2] Weiner, H. L. (2004). Multiple sclerosis is an inflammatory T-cell-mediated 509 autoimmune disease. Arch Neurol, 61, 1613-1615. 510 [3] Miller, D. H., Chard, D. T., Ciccarelli, O. (2012). Clinically isolated syndromes. 511 Lancet Neurol, 11, 157-169. Giovannoni, G., Butzkueven, H., Dhib-jalbut, S., Hobart, J., Kobelt, G., Pepper. 512 [4] 513 G., ... Vollmer, T. (2016). Brain health: time matters in multiple sclerosis. Mult 514 Scler Relat Disord, 9, S5-S48. 515 Macaron, G., Ontaneda, D. (2019). Diagnosis and management of progressive [5] 516 multiple sclerosis. Biomedicines. 7.56. 517 [6] Miller, J. R. (2004). The importance of early diagnosis of multiple sclerosis. J 518 Manag Care Pharm, 10, S4-S11. 519 Goldschmidt, T., Antel, J., König, F. B., Brück, W., Kuhlmann, T. (2009). [7] 520 Remyelination capacity of the MS brain decreases with disease chronicity. 521 Neurology, 72, 1914-1921. Cunniffe, N., Coles, A. (2021). Promoting remyelination in multiple sclerosis. J 522 [8] 523 Neurol, 268, 30-44. 524 [9] McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H.-P., Lublin, 525 F. D., . . . Wolinsky, J. S. (2001). Recommended diagnostic criteria for multiple 526 sclerosis: guidelines from the international panel on the diagnosis of multiple 527 sclerosis. Ann Neurol, 50, 121-127. Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., 528 [10] 529 Comi, G., . . . Cohen, J. A. (2018). Diagnosis of multiple sclerosis: 2017 530 revisions of the McDonald criteria. Lancet Neurol, 17, 162-173. 531 Tintoré, M., Rovira, A., Río, J., Nos, C., Grivé, E., Téllez, N., . . . Montalban, X. [11] 532 (2006). Baseline MRI predicts future attacks and disability in clinically isolated 533 syndromes. Neurology, 67, 968-972. Teixeira, M., Seabra, M., Carvalho, L., Sequeira, L., Abreu, P., Mendonça, T., . 534 [12] 535 . . Guimarães, J. (2020). Clinically isolated syndrome, oligoclonal bands and 536 multiple sclerosis. Clin Exp Neuroimmunol, 11, 33-39. 537 [13] Jafari, A., Babajani, A., Rezaei-Tavirani, M. (2021). Multiple sclerosis 538 biomarker discoveries by proteomics and metabolomics approaches. *Biomark* 539 Insights, 16, 11772719211013352. 540 Ziemssen, T., Akgün, K., Brück, W. (2019). Molecular biomarkers in multiple [14] 541 sclerosis. J Neuroinflammation. 16, 272. Gul, M., Jafari, A. A., Shah, M., Mirmoeeni, S., Haider, S. U., Moinuddin, S., 542 [15] 543 Chaudhry, A. (2020). Molecular biomarkers in multiple sclerosis and its related 544 disorders: a critical review. Int J Mol Sci, 21, 6020. Hühmer, A. F., Biringer, R. G., Amato, H., Fonteh, A. N., Harrington, M. G. 545 [16] (2006). Protein analysis in human cerebrospinal fluid: physiological aspects, 546 547 current progress and future challenges. Dis Markers, 22, 3-26. 548 [17] Zhang, J. (2007). Proteomics of human cerebrospinal fluid – the good, the 549 bad, and the ugly. Proteomics Clin Appl, 1, 805-819. 550 Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., [18] 551 Thompson, A. J., . . . Polman, C. H. (2014). Defining the clinical course of 552 multiple sclerosis: the 2013 revisions. Neurology, 83, 278-286. 553 Assarsson, E., Lundberg, M., Holmquist, G., Björkesten, J., Bucht Thorsen, S., [19] 554 Ekman, D., . . . Fredriksson, S. (2014). Homogenous 96-plex PEA

	Qures	ni et al Biomarker Analytical Validation Manuscript MedRxiv
555		immunoassay exhibiting high sensitivity, specificity, and excellent scalability.
556		PLoS One, 9, e95192.
557	[20]	Schubert, O. T., Röst, H. L., Collins, B. C., Rosenberger, G., Aebersold, R.
558		(2017). Quantitative proteomics: challenges and opportunities in basic and
559		applied research. Nat Protoc, 12, 1289-1294.
560	[21]	Dillon, R., Croner, L. J., Bucci, J., Kairs, S. N., You, J., Beasley, S., Wilcox,
561		B. (2018). Analytical validation of a novel multiplex test for detection of
562		advanced adenoma and colorectal cancer in symptomatic patients. J Pharm
563		Biomed Anal, 154, 85-94.
564	[22]	Eastman, P. S., Manning, W. C., Qureshi, F., Haney, D., Cavet, G., Alexander,
565		C., Hesterberg, L. K. (2012). Characterization of a multiplex, 12-biomarker test
566		for rheumatoid arthritis. J Pharm Biomed Anal, 70, 415-424.
567	[23]	Chitnis, T., Prat, A. (2020). A roadmap to precision medicine for multiple
568		sclerosis. Multiple Sclerosis Journal, 26, 522-532.
569	[24]	Bhawal, R., Oberg, A. L., Zhang, S., Kohli, M. (2020). Challenges and
570		opportunities in clinical applications of blood-based proteomics in cancer.
571	r	Cancers (Basel), 12, 2428.
572	[25]	Chitnis, I., Becich, M., Bove, R., Cree, B. A. C., Gehman, V., Gomez, R.,
573		Baranzini, S. E. Development of a custom multivariate proteomic serum based
5/4		assay for association with radiographic and clinical endpoints in MS.
5/5		Presented at: Americas Committee for Treatment and Research in Multiple
5/0 577		Scierosis and European Commilee for Treatment and Research in Multiple
511 570	[26]	Chitnia T. Foloy, J. Jonato, C. El Avoubi, N. Savona, S. Caitan Walch, P.
570	[20]	Khoury S. I. Clinical validation study results of a multivariate proteomic
580		serum based assay for disease activity assessments in multiple sclerosis
581		Presented at: 37th Congress of the European Committee for Treatment and
582		Research in Multiple Sclerosis (ECTRIMS): October 13-15, 2021: Virtual
583	[27]	Clinical and Laboratory Standards Institute, (2018), EP283CE, Defining.
584	[=.]	establishing, and verifying reference intervals in the clinical laboratory. 3rd
585		edition.
586	[28]	Hancox, T. P. M., Skene, D. J., Dallmann, R., Dunn, W. B. (2021). Tick-tock
587		consider the clock: the influence of circadian and external cycles on time of
588		day variation in the human metabolome—a review. Metabolites, 11, 328.
589	[29]	United States Food and Drug Administration. Bioanalytical method validation:
590		guidance for industry. Accessed September 13, 2021.
591		https://www.fda.gov/media/70858/download
592	[30]	Clinical and Laboratory Standards Institute. (2016). EP07. Interference testing
593	_	in clinical chemistry. 3rd edition.
594	[31]	Xu, Y. W., Peng, Y. H., Chen, B., Wu, Z. Y., Wu, J. Y., Shen, J. H., Xu, L.
595		Y. (2014). Autoantibodies as potential biomarkers for the early detection of
596	10.01	esophageal squamous cell carcinoma. Am J Gastroenterol, 109, 36-45.
597	[32]	Yang, X., Suo, C., Zhang, T., Yin, X., Man, J., Yuan, Z., Ye, W. (2021).
598 500		argeted proteomics-derived biomarker profile develops a multi-protein
399 600		classifier in liquid biopsies for early detection of esophageal squamous cell
000 601	[22]	University of the second study of the second study. Biomark Res, 9, 12.
602	႞ၖၖ႞	Filazi, Z., Wallehull, L., Lihuback, J., Alexanuel, J. H., Connolly, S. J., Fikalboom, J. W., Siaababa, A. (2020). Screening of multiple biomerican
602		associated with ischemic stroke in atrial fibrillation <i>I Am Hoart Assoc</i> 0
604		e018984
501		

medRxiv preprint doi: https://doi.org/10.1101/2022.05.23.22275201; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Qureshi et al **Biomarker Analytical Validation Manuscript** MedRxiv 605 [34] Sanders-van Wijk, S., Tromp, J., Beussink-Nelson, L., Hage, C., Svedlund, S., Saraste, A., . . . Shah, S. J. (2020). Proteomic evaluation of the comorbidity-606 inflammation paradigm in heart failure with preserved ejection fraction: results 607 608 from the PROMIS-HFpEF study. Circulation, 142, 2029-2044. 609 [35] Pol, T., Hijazi, Z., Lindbäck, J., Oldgren, J., Alexander, J. H., Connolly, S. J., . . 610 . Wallentin, L. (2021). Using multimarker screening to identify biomarkers 611 associated with cardiovascular death in patients with atrial fibrillation. 612 Cardiovasc Res, cvab262. Feldreich, T., Nowak, C., Fall, T., Carlsson, A. C., Carrero, J. J., Ripsweden, 613 [36] 614 J., . . Arnlöv, J. (2019). Circulating proteins as predictors of cardiovascular 615 mortality in end-stage renal disease. J Nephrol, 32, 111-119. Nowak, C., Carlsson, A. C., Östgren, C. J., Nyström, F. H., Alam, M., 616 [37] Feldreich, T., . . . Ärnlöv, J. (2018). Multiplex proteomics for prediction of major 617 618 cardiovascular events in type 2 diabetes. Diabetologia, 61, 1748-1757. Leandersson, P., Åkesson, A., Hedenfalk, I., Malander, S., Borgfeldt, C. 619 [38] 620 (2020). A multiplex biomarker assay improves the diagnostic performance of 621 HE4 and CA125 in ovarian tumor patients. PLoS One, 15, e0240418. 622 [39] Enroth, S., Berggrund, M., Lycke, M., Broberg, J., Lundberg, M., Assarsson, 623 E.,... Gyllensten, U. (2019). High throughput proteomics identifies a high-624 accuracy 11 plasma protein biomarker signature for ovarian cancer. Commun 625 Biol, 2, 221. Berggrund, M., Enroth, S., Lundberg, M., Assarsson, E., Stålberg, K., 626 [40] 627 Lindquist, D., . . . Gyllensten, U. (2019). Identification of candidate plasma 628 protein biomarkers for cervical cancer using the multiplex proximity extension 629 assay. Mol Cell Proteomics, 18, 735-743. 630 [41] Whelan, C. D., Mattsson, N., Nagle, M. W., Vijayaraghavan, S., Hyde, C., Janelidze, S., . . . Hansson, O. (2019). Multiplex proteomics identifies novel 631 632 CSF and plasma biomarkers of early Alzheimer's disease. Acta Neuropathol Commun, 7, 169. 633 634 [42] Petrackova, A., Smrzova, A., Gajdos, P., Schubertova, M., Schneiderova, P., Kromer, P., . . . Kriegova, E. (2017). Serum protein pattern associated with 635 636 organ damage and lupus nephritis in systemic lupus erythematosus revealed 637 by PEA immunoassay. Clin Proteomics, 14, 32. 638 [43] Brunner, P. M., He, H., Pavel, A. B., Czarnowicki, T., Lefferdink, R., Erickson, T., ... Paller, A. S. (2019). The blood proteomic signature of early-onset 639 640 pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long-standing disease. J Am Acad Dermatol, 81, 510-519. 641 [44] Moaddel, R., Ubaida-Mohien, C., Tanaka, T., Lvashkov, A., Basisty, N., 642 643 Schilling, B., . . . Ferrucci, L. (2021). Proteomics in aging research: a roadmap 644 to clinical, translational research. Aging Cell, 20, e13325. 645

	medRxiv preprint doi: https preprint (which was not	s://doi.org/10.1101/2022.05.23.22275201; this version posted January 31, 2023. certified by peer review) is the author/funder, who has granted medRxiv a license perpetuity.	The copyright holder for this e to display the preprint in					
	Qureshi et al	Biomarker Analytical Validation Manuscript	MedRxiv					
646 647	FIGURE LEGE	NDS						
648	FIGURE 1. Incu	urred sample reanalysis results for (A) Individual bioma	arkers and (B)					
649	Overall Disease Activity score, (C) Immunomodulation, (D) Neuroinflammation, (E)							
650	Myelin Biology,	Myelin Biology, and (F) Neuroaxonal Integrity pathway scores in the MSDA Test.						
651								
652	FIGURE 2. Acc	uracy of the MSDA Test to detect (A) Individual bioma	arkers and (B)					
653	Overall Disease	Activity score, (C) Immunomodulation, (D) Neuroinfla	ammation, (E)					
654	Myelin Biology,	and (F) Neuroaxonal Integrity pathway scores.						
655								
656	FIGURE 3. Ass	ay interference for common MS drugs, DMTs, and the	ə high					

657 concentration of universal mAb surrogates in the MSDA Test.

All rights reserved. No reuse allowed without permission.

Qureshi et al

Biomarker Analytical Validation Manuscript

MedRxiv

FIGURE 1



Qureshi et al

Biomarker Analytical Validation Manuscript

MedRxiv

FIGURE 2



Qureshi et al

Biomarker Analytical Validation Manuscript

MedRxiv

FIGURE 3



MedRxiv

TABLES

TABLE 1 Intra- and inter-assay precision, sensitivity, and reference ranges for biomarkers in the MSDA Test

	Precision												Sensitivity a	and reference	e ranges			
Analytes	Sho	rter MS o pool ^a	duration	Longe	er MS dura	tion pool ^b		RA poo	bl	Heal	thy cont	rol pool						
	Intra %CV	Inter %CV	Conc (pg/mL)	Intra %CV	Inter %CV	Conc (pg/mL)	Intra %CV	Inter %CV	Conc (pg/mL)	Intra %CV	Inter %CV	Conc (pg/mL)	LLOQ (pg/mL)	ULOQ (pg/mL)	Low MS range (pg/mL) ^c	High MS range (pg/mL) ^d	Samples imputed at LLOQ, % (<i>N</i> =1645)	Samples imputed at ULOQ, % (<i>N</i> =1645)
APLP1	9	9	10,296	9	8	11,560	4	8	11,868	7	9	11,868	2323.78	142,798.49	5500	22,000	0	0
CCL20	6	9	6.9	8	7	9.2	5	9	13.7	7	9	11.8	0.92	383.49	2.1	52	0	1 (<0.1)
CD6	6	8	89	8	8	108	5	7	137	8	9	112	4.62	3318.60	46	250	0	0
CDCP1	8	9	78	8	9	125	4	9	208	7	10	72	24.22	6795.04	28	230	23 (1.4)	1 (<0.1)
CNTN2	6	7	1120	7	7	1643	4	6	1554	8	8	1256	44.46	12,373.51	650	3300	0	0
COL4A1	7	15	1104	19	20	1334	8	59	1601	47	27	1387	30.65	4573.38	520	3600	0	23 (1.4)
CXCL13	6	8	52.8	8	7	42.9	7	8	65.3	7	9	46.8	1.91	1112.70	22	190	0	0
CXCL9	6	11	31.0	8	10	62.6	5	11	112.3	7	11	27.5	1.89	1832.22	17	250	0	0
FLRT2	7	8	103	9	9	110	5	8	139	8	9	116	35.67	10,107.17	63	180	1 (<0.1)	0
GFAP	7	18	70	10	16	126	8	15	148	9	18	77	12.46	19,582.88	24	220	16 (1.0)	0
GH	7	9	823	8	7	595	5	8	1010	7	9	366	9.63	18,413.83	17	9500	7 (0.4)	9 (0.5)
IL-12β	7	9	109	9	7	122	6	8	118	8	9	71	0.56	3044.33	28	280	0	0
MOG	4	6	21.9	7	6	22.8	5	7	26.0	6	8	17.8	1.75	577.42	12	47	0	0
NfL	10	11	7.6	13	9	15.6	8	8	20.6	11	12	6.5	3.31	599.18	3.5	42	29 (1.8)	0
OPG	6	11	699	9	11	806	6	10	1022	7	12	602	14.58	62,385.21	410	1400	0	0
OPN	6	10	15,733	7	10	15,415	6	12	17,470	7	13	10,450	572.50	157,267.29	9500	39,000	0	0
PRTG	7	6	94	8	7	107	5	6	108	7	7	103	3.90	5920.73	71	180	2 (0.1)	0
SERPINA9	11	8	45.1	11	8	37.9	5	7	60.0	6	14	50.0	5.12	9286.67	12	160	1 (<0.1)	0
TNFRSF10 A	9	9	5.1	9	9	5.5	5	8	7.6	9	9	4.9	0.48	1027.28	2.8	9.7	0	0
TNFSF13B	7	10	4075	11	11	4019	5	11	4204	7	13	3003	660.29	130,682.08	2300	10,000	0	0
VCAN	7	8	316	7	7	337	4	7	448	5	8	310	8.54	14,673.95	230	600	0	0

Green shading: intra- (%CV ≤15%) or inter-assay (%CV <20%) are within the acceptability range for the assays. Red shading: intra- (%CV >15%) or inter-assay (%CV ≥20%) precision values are outside the acceptability range for

the assays.

Qureshi et al Biomarker Analytical Validation Manuscript

MedRxiv

 $^{\rm a}\text{Average}$ age of patients with shorter MS duration was 36 (range, 27–43) years.

- $^{\mathrm{b}}\textsc{Average}$ age of patients with longer MS duration was 52 (range, 45–62) years.
- $^{\rm c}\text{Low}$ MS range was defined as the 2.5th percentile.
- ^dHigh MS range was defined as the 97.5th percentile.

medRxiv preprint doi: https://doi.org/10.1101/2022.05.23.22275201; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission. **Biomarker Analytical Validation Manuscript**

MedRxiv

TABLE 2 Diurnal variability of eight samples in the MSDA Test across six time

points (days 1, 2, 3, 4, 5, and 12)

Qureshi et al

ANALYTE	MEAN %CV	MEDIAN %CV
APLP1	14	15
CCL20	25	21
CD6	10	7
CDCP1	12	12
CNTN2	11	10
COL4A1	44	39
CXCL13	18	11
CXCL9	13	11
FLRT2	10	8
GFAP	13	12
GH	78	79
IL-12в	10	9
MOG	12	11
NFL	17	17
OPG	11	10
OPN	10	8
PRTG	8	6
SERPINA9	12	12
TNFRSF10A	10	12
TNFSF13B	11	8
VCAN	10	7

Green shading: %CV ≤30%. Red shading: %CV >30%.

medRxiv preprint doi: https://doi.org/10.1101/2022.05.23.22275201; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity.

All rights reserved. No reuse allowed without permission. Biomarker Analytical Validation Manuscript Proteomics Clin Appl

Analytical Validation of a multi-protein, proteomic serum-based assay for disease activity assessments in multiple sclerosis

Ferhan Qureshi,* Wayne Hu,* Louisa Loh, Hemali Patel, Maria DeGuzman, Michael Becich, Fatima Rubio da Costa, Victor Gehman, Fujun Zhang, John Foley, Tanuja Chitnis

*These authors contributed equally to this work

Qureshi et al

Supporting Information

Qureshi et al Biomarker Analytical Validation Manuscript

Proteomics Clin Appl

FILE S1. MSDA Test algorithm formula

Key to the MSDA Test was the architecture of a stacked classifier (in the mlxtend [1] framework) where each node (blue boxes in the Figure) in both layers are L2regularized logistic regression models from Scikit Learn.[2] The input layer read in demographically corrected for age and sex, log₁₀ LOQ-imputed concentrations of proteins associated with four physiological pathways from each sample and generated probabilities that the sample in question was positive for the presence of Gd+lesions. The meta-classifier (output) layer of the model ingested the probabilities from each pathway model along with all of the protein concentrations that fed the first layer and generated an overall probability that the sample in guestion was Gd+ lesion-positive. This probability was then mapped into a Disease Activity score by being shifted, scaled, rounded, and clipped to the nearest half point over a range from 1 to 10 (Eq. 1). A similar process converted the pathway probabilities into pathway scores after the pathway probabilities were adjusted so that for each sample, the mean over the adjusted pathway probabilities was equal to the Disease Activity probability for each sample (Eq. 2). The datasets used to develop and evaluate the demographic correction, four Disease Pathway models, and Disease Activity model, as well as the performance of these models, have been described previously.[2]

The process for calculating the Disease Activity score is shown in the **Figure**.

 medRxiv preprint doi: https://doi.org/10.1101/2022.05.23.22275201; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

 All rights reserved. No reuse allowed without permission.

 Qureshi et al
 Biomarker Analytical Validation Manuscript
 Proteomics Clin Appl

 FIGURE. Schematic representation of the Disease Activity score calculation from protein concentrations (green) to both layers of the stacked classifier (blue), the output Disease Activity probability (red), and the final Disease Activity and Disease

Pathway score (black).



The overall Disease Activity score had the mathematical form:

$$S_{DA} = \operatorname{Clip} {}_{0}^{9} \left(\frac{1}{2} \operatorname{Round} \left(18 \times \frac{P_{DA} - P_{DA}^{Low}}{P_{DA}^{High} - P_{DA}^{Low}} \right) \right) + 1$$
(1)

The "Clip" function limited the output of its argument to between 0 and 9. The "Round" function rounded to the nearest whole number. P_{DA} was the Disease Activity probability output from the final stage of the stacked classifier model. P^{High}_{DA} and

medRxiv preprint doi: https://doi.org/10.1101/2022.05.23.22275201; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
 All rights reserved. No reuse allowed without permission.
 Qureshi et al Biomarker Analytical Validation Manuscript Proteomics Clin Appl
 P^{Low}_{DA} were probability clip values chosen for the overall Disease Activity (and each pathway) to maximize the range of the score over the entire training data set. Their values are tabulated below.

Similar to the Disease Activity score, each pathway score was computed from the pathway probabilities with the additional step of recentering the ensemble of pathway probabilities around the Disease Activity probability for each sample:

$$S_{pth} = \text{Clip}_{0}^{9} \left(\frac{1}{2} \text{Round} \left(18 \times \left(\frac{P_{pth} - P_{pth}^{Low}}{P_{pth}^{High} - P_{pth}^{Low}} + \frac{P_{DA} - P_{DA}^{Low}}{P_{DA}^{High} - P_{DA}^{Low}} - \frac{1}{N_{pth}} \sum_{pth'} \frac{P_{pth'} - P_{pth'}^{Low}}{P_{pth'}^{High} - P_{pth'}^{Low}} \right) \right) \right) + 1$$
(2)

"Clip" and "Round" served the same purpose in Eq. 2 as in Eq.1. P_{pth} was the probability for pathway model *pth*. P_{DA} was again the probability output by the final stage of the stacked classifier. The "High" and "Low" Ps for each *pth* served a similar purpose to those for the Disease Activity: rescaling the model probabilities so that they had a larger dynamic range. Lastly, N_{pth} was the number of pathway models that fed into the final layer of the stacked classifier model. In this case, $N_{pth}=4$.

The probabilities associated with each layer of the stacked classifier had a closed analytic form as well. Working backward from the final Disease Activity score, the Disease Activity probability had the form:

$$P_{DA} = \frac{1}{1 + e^{-\left(C_{DA}^{0} + \sum_{feat} C_{feat} V_{feat}\right)}}$$
(3)

 C^{0}_{DA} was the intercept (or bias) value for the Disease Activity meta-classifier. C_{feat} was the coefficient associated with V_{feat} . V_{feat} was the value of the feature being summed, either the probability for one of the pathways from the first layer of the model (written out explicitly in Eq. 4) or the age- and sex- corrected, log₁₀, LOQimputed concentrations that fed into the first-layer pathway models. These meta-

 medRxiv preprint doi: https://doi.org/10.1101/2022.05.23.22275201; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

 All rights reserved. No reuse allowed without permission.

 Qureshi et al
 Biomarker Analytical Validation Manuscript
 Proteomics Clin Appl

 classifier coefficients were fit using L2-penalized logistic regression with Gd+ lesion

 presence as the dependent variable, an intercept, and the stacked classifier features

 as the independent variables, with inverse regularization strength C=1.0, balanced

 class weight, and tolerance =0.0001, with the 'lbfgs' solver.

The individual pathway probabilities had the form:

$$P_{pth} = \frac{1}{1 + e^{-(C_{pth}^0 + \sum_{prot} C_{prot} V_{prot})}}$$
(4)

 C^{0}_{pth} was the intercept value for the pathway model in question. C_{prot} was the coefficient for a protein in pathway *pth*. V_{prot} was the demographically corrected, log₁₀, LOQ-imputed concentration of protein *prot*. These coefficients were fit using L2-penalized logistic regression with Gd+ lesion presence as the dependent variable, an intercept, and the pathway's demographically corrected (for age, sex), log₁₀, LOQ-imputed protein concentrations as the independent variables. The final pathway coefficients were the result of a stratified, 10-fold cross-validation with 3 repeats, grid-searched over inverse regularization strength C=[100, 10, 1.0, 0.1, 0.01], class weights=[None, balanced], solvers=["saga," "lbfgs," "liblinear"], and tolerances=[0.01, 0.001, 0.0001]. The demographic correction for the log₁₀ of the LOQ-imputed protein concentration had the form:

$$V_{prot} = \log_{10} \left(A_{prot} \left[\frac{pg}{mL} \right] \right) - \left[D_{prot,0} + \left(D_{prot,Sex} \times Sex \right) + \left(D_{prot,Age} \times Age[years] \right) \right]$$
(5)

 A_{prot} was the LOQ-imputed absolute concentration of protein *prot* in pg/mL (the units of these direct measurements have been written explicitly for added clarity). $D_{prot, 0}, D_{prot, Sex}$, and $D_{prot, Age}$ were the intercept, sex, and age coefficients for demographic correction, respectively. These coefficients were fit using the following procedure on three datasets not reported here. The dataset used to train the stacked classifier and pathway models provided the final non-zero coefficients for the

perpetuity. All rights reserved. No reuse allowed without permission.

Qureshi et alBiomarker Analytical Validation ManuscriptProteomics Clin Appldemographic correction. The demographic correction coefficients were fitindependently on each dataset using linear regression using StatsModels OLS[4]with log10, LOQ-imputed protein concentration as the dependent variable, anintercept, and age and sex as the independent variables, after outliers were removed.Outliers were defined for each dataset as \geq 96th percentile or \leq 4th percentile for log10,LOQ-imputed protein concentration. After fitting the linear regression, the age andsex coefficients were set to zero if the 95% confidence interval contained zero in anyof the three datasets or if the sign of the coefficient was not consistent across threedatasets. Sex was 0 for women and 1 for men, and age was the patient's age inyears at time of blood draw.

Finally, see below for tables of the coefficients used in each step of the scoring process. First, we tabulated the demographic correction coefficients. These were the *D*s in Eq. 5.

Protein	Sex	Age	Intercept
APLP1	-0.052	0	4.065
CCL20	0	0	1.088
CD6	0	0	1.959
CDCP1	0	0.006	1.64
CNTN2	0	0.002	3.128
CXCL13	0	0	1.819
CXCL9	0	0.005	1.419
FLRT2	0	0	1.968
GFAP	-0.05	0.005	1.692
IL-12B	0	0	2.062
MOG	-0.04	0.003	1.267
NfL	0	0.008	0.5
OPG	-0.014	0.002	2.743

Qureshi et al

Biomarker Analytical Validation Manuscript

Proteomics Clin Appl

OPN	0.045	0	4.172
PRTG	0	0	2.052
SERPINA9	0	0	1.56
TNFRSF10A	0	0.003	0.565
TNFSF13B	0	0	3.75

Next, we tabulated the protein coefficients for each pathway. These were the

Cs in Eq. 4.

Neuroinflammation: •

Feature	Coefficient
CCL20	0.397
CD6	0.243
CXCL13	0.668
CXCL9	0.778
IL-12B	-1.515
TNFRSF10A	0.089
TNFSF13B	-2.705
Intercept	-0.283

Immunomodulation: •

Feature	Coefficient
CD6	0.825
CDCP1	-0.633
CXCL13	1.075
CXCL9	1.178
IL-12B	-1.657
TNFSF13B	-4.232
Intercept	-0.483

Biomarker Analytical Validation Manuscript

Proteomics Clin Appl

- Qureshi et al
 - Neuroaxonal Integrity:

Feature	Coefficient
APLP1	-0.149
CNTN2	-0.434
FLRT2	-0.321
GFAP	0.024
NfL	2.998
OPG	0.384
OPN	0.026
PRTG	-0.621
SERPINA9	-0.779
TNFRSF10A	-0.284
Intercept	-0.744

Myelin Biology: •

Feature	Coefficient
APLP1	-1.206
MOG	2.653
OPN	-0.037
Intercept	-0.552

Then we tabulated the meta-classifier coefficients for the second stage of the

stacked classifier. These were the Cs in Eq. 3.

Feature	Coefficient
APLP1	-0.363
CCL20	0.222
CD6	0.119
CDCP1	-0.524
CNTN2	-0.21
CXCL13	0.1
CXCL9	0.252
FLRT2	-0.111

Qureshi et al

Biomarker Analytical Validation Manuscript

Proteomics Clin Appl

GFAP	0.042
IL-12B	-0.432
MOG	0.485
NfL	2.038
OPG	0.056
OPN	-0.072
PRTG	0.768
SERPINA9	0.142
TNFRSF10A	-0.178
TNFSF13B	-1.3
Neuroinflammation pathway	
classifier	1.14
Immunomodulation pathway	
classifier	1.737
Neuroaxonal integrity pathway	
classifier	1.525
Myelin biology pathway	
classifier	0.435
Intercept	-2.51

Finally, we tabulated the low and high values for scaling the probabilities in

Eq.1 and Eq.2.

Disease Pathway/Disease Activity score	P Low pth	P High pth
Disease Pathway		
Immunomodulation	0.05	1.0
Myelin Biology	0.2	0.6
Neuroaxonal Integrity	0.1	1.0
Neuroinflammation	0.15	0.95
Disease Activity	0.05	1.00

Abbreviations: P_{High pth}, high values for scaling probabilities; P_{Low pth}, low values for scaling probabilities.

Biomarker Analytical Validation Manuscript

Proteomics Clin Appl

FILE S2. Assay interferents

Qureshi et al

Samples were analyzed for potential interference with endogenous substances found naturally in patients' samples (eg, lipemia, hemolysis, high protein count, and high bilirubin levels) and heterophilic antibodies such as HAMA and RF. Serum pools (n=4) were spiked with bilirubin, hemolysate, and lipids at typical concentrations using the ASSURANCE[™] Interference Test Kit (Sun Diagnostics).

Heterophilic antibodies, including RF and HAMA, are established sources of potential interference in immunoassays. RF concentrate (Lee BioSolutions, Maryland Heights, MO, USA) was used to spike six serum samples at low (150 IU/mL) and high (2000 IU/mL) concentrations to determine the effect of RF interference on the analysis. For HAMA interference, five HAMA-positive serum samples with known established HAMA levels (ASSURANCE™ Interference Test Kit) were mixed at different ratios (10:90; 50:50; 90:10) with four MS samples from an internal cohort. Two HAMA-positive samples had a titer level >240 and three samples had a titer level >480, indicating that the positive samples had either >240 or >480 times more activity than a known negative. The mixed samples were compared with expected ratios of the individually measured samples to calculate the percent recovery.

Except for heterophilic antibody interference, the mean percentage recovery was calculated relative to the corresponding spike control (representing the same alteration of the serum sample without the addition of the interferent). For heterophilic antibody interference, the mean percentage recovery was calculated by comparing the RF spiked (low and high concentrations) samples with a corresponding spike control.

	All rights reserved. No reuse allowed without permission.	
Qureshi et al	Biomarker Analytical Validation Manuscript	Proteomics Clin Appl

TABLE S1 Protein biomarkers included in assay panel to perform the MSDA Test

Biomarker	Full name	UniProt identifier
APLP1	Amyloid beta precursor-like protein 1	P51693
CCL20	C-C motif chemokine ligand 20 (MIP 3-alpha)	P78556
CD6	Cluster of differentiation 6	P30203
CDCP1	CUB domain-containing protein 1	Q9H5V8
CNTN2	Contactin 2	Q02246
CXCL13	Chemokine (C-X-C motif) ligand 13	P02462
CXCL9	Chemokine (C-X-C motif) ligand 9 (MIG)	O43927
COL4A1ª	Collagen type IV alpha 1	Q07325
FLRT2	Fibronectin leucine-rich repeat transmembrane protein	O43155
GFAP	Glial fibrillary acidic protein	P14136
GH ^a	Growth hormone (somatotropin)	P01241
IL-12β	Interleukin-12 subunit beta	P29460
MOG	Myelin oligodendrocyte glycoprotein	Q16653
NfL	Neurofilament light polypeptide chain	P07196
OPG	Osteoprotegerin	O00300
OPN	Osteopontin	P10451
PRTG	Protogenin	Q2VWP7
SERPINA9	Serpin family A member 9	Q86WD7
TNFRSF10A	Tumor necrosis factor receptor superfamily member 10A (TRAIL-R1)	O00220
TNFSF13B	Tumor necrosis factor superfamily member 13B (BAFF)	Q9Y275
VCAN ^a	Versican core protein	P13611

^aThese biomarkers were not used in the algorithm to determine Disease Pathway and Disease Activity scores.

medRxiv preprint doi: https://doi.org/10.1101/2022.05.23.22275201; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

- perpetuity. All rights reserved. No reuse allowed without permission.
- Qureshi et alBiomarker Analytical Validation ManuscriptProteomics Clin Appl

TABLE S2 Common over-the-counter and prescription drugs, reference materials

and standards, and mAbs evaluated for interference in the MSDA Test

Assay interferents	Concentration
Common drugs	
Acetaminophen	15.6 mg/dL
Ampicillin Na	7.5 mg/dL
Acetylsalicylic acid	3 mg/dL
Doxycycline HCI	1.8 mg/dL
Cefoxitin Na	660 mg/dL
Heparin	3300 U/L
Cyclosporine	0.18 mg/dL
Levodopa	0.75 mg/dL
Ibuprofen	21.9 mg/dL
Methyldopa	2.25 mg/dL
Phenylbutazone	32.1 mg/dL
Metronidazole	12.3 mg/dL
Rifampicin	4.8 mg/dL
Theophylline	6 mg/dL
Acetylcysteine	15 mg/dL
Reference materials and standards to evaluate DMTs	
Interferon β-1A (Avonex, Rebif)	0.56 ng/mL
Dimethyl fumarate (Tecfidera)	3.74 μg/mL
Fingolimod (Gilenya)	8.8 ng/mL
Teriflunomide (Aubagio)	90.6 µg/mL
Mitoxantrone (Novantrone)	0.674 µg/mL
Rituximab (Rituxan)	370 μg/mL
Methylprednisolone	0.141 µg/mL
Cladribine (Mavenclad)	0.058 µg/mL
Glatiramer acetate (Copaxone, Glatopa)	1.0 µg/mL
Vitamin D2 (Ergocalciferol)	0.2 µg/mL

medRxiv preprint doi: https preprint (which was not o	://doi.org/10.1101/2022.05.23.22275201; this version posted Janua certified by peer review) is the author/funder, who has granted med perpetuity. All rights reserved. No reuse allowed without permission	ary 31, 2023. The copyright holder for this IRxiv a license to display the preprint in on.
Qureshi et al	Biomarker Analytical Validation Manuscript	Proteomics Clin Appl
Universal mAb	surrogates ^a	
High conce	ntration	424 µg/mL
Low concer	itration	7.93 μg/mL

^aSurrogates for natalizumab, ocrelizumab, alemtuzumab, and ofatumumab.

- Qureshi et al **Biomarker Analytical Validation Manuscript** Proteomics Clin Appl

TABLE S3 Lot to lot (batch 1 vs. batch 2) and laboratory to laboratory (development

vs. clinical laboratory) consistency of the MSDA Test

	Mean %	difference	R ² correlation	on of samples					
	Batch 1 vs. batch 2	Development vs. clinical laboratory	Batch 1 vs. batch 2	Development vs. clinical laboratory					
APLP1	0	-1	0.93	0.95					
CCL20	-14	-12	0.99	1.00					
CD6	-9	-9	0.97	0.97					
CDCP1	-9	-10	0.99	1.00					
CNTN2	8	4	0.96	0.97					
COL4A1	-27	-17	0.97	0.98					
CXCL13	-7	-5	0.99	1.00					
CXCL9	-16	-11	1.00	1.00					
FLRT2	-3	-6	0.95	0.98					
GFAP	-13	-9	0.96	0.97					
GH	-3	-6	0.98	0.99					
IL-12β	-5	-5	0.97	0.98					
MOG	2	0	0.98	0.98					
NfL	-13	-10	0.98	0.99					
OPG	-17	-9	0.97	0.98					
OPN	-14	-7	0.97	0.99					
PRTG	0	-5	0.97	0.98					
SERPINA9	-4	-5	0.99	0.99					
TNFRSF10 A	-7	-11	0.98	0.99					
TNFSF13B	-6	-5	0.96	0.98					
VCAN	-8	-9	0.91	0.95					

TABLE S4 Storage, processing, and stability of the individual biomarkers at various temperatures (room temperature, 4°C, and

-20°C) over time during the initial and follow-up studies

	Mean % difference vs. experimental control conditions																				
								In	itial stu	dy								Follow-up study			
		Ro	oom ter	nperatu	ıre				4	°C					−20°C			4°C			
Analyte	4 h	Day 1	Day 3	Day 7	Day 14	Day 28	4 h	Day 1	Day 3	Day 7	Day 14	Day 28	Day 1	Day 3	Day 7	Day 14	Day 28	Day 1	Day 2	Day 3	Day 7
APLP1	4	17	7	19	48	134	-6	-8	12	31	12	25	5	9	0	5	10	10	5	7	11
CCL20	4	2	-6	-7	8	47	1	-3	11	24	15	23	12	13	6	5	7	-1	-2	4	12
CD6	-2	-4	-14	-5	19	93	-10	-11	-7	7	-2	10	1	5	-1	1	1	2	-1	2	5
CDCP1	-5	-1	-13	-2	26	114	-10	-10	-2	6	1	10	0	7	-3	1	1	4	1	3	4
CNTN2	0	-3	-13	-3	24	71	-8	-10	-9	2	-3	7	2	6	1	2	3	3	0	1	1
COL4A1	-5	-3	-14	-1	22	91	-10	-11	-12	2	-2	10	0	4	9	3	2	9	-3	11	14
CXCL13	-1	-7	-25	-27	-24	7	-5	-6	-8	-6	-4	-3	6	12	4	7	5	2	0	0	1
CXCL9	-2	-4	-14	-7	16	65	-6	-10	-11	-4	-6	-2	2	6	1	3	4	4	0	1	0
FLRT2	-4	-1	-11	0	26	97	-10	-10	-2	11	2	13	-1	8	-1	1	2	3	0	2	3
GFAP	0	2	-5	9	39	142	-7	-9	-5	20	1	18	3	11	-1	3	9	1	3	4	8
GH	1	0	-10	-6	9	52	-6	-9	2	10	7	12	4	9	1	5	7	2	3	2	10
IL-12β	-2	-13	-34	-40	-32	-24	-7	-11	-14	-18	-9	-15	3	8	0	3	4	3	0	1	-4
MOG	-2	0	-10	1	23	83	-7	-9	-1	13	2	12	1	6	1	3	3	1	2	1	3
NfL	-3	-6	-11	2	29	110	-11	-9	1	4	3	12	-4	4	0	2	2	-3	6	1	6
OPG	-2	-4	-13	-5	18	94	-6	-9	-8	1	-1	5	1	6	-1	2	2	2	0	1	1
OPN	-4	-5	-18	-13	1	47	-6	-16	-27	-24	-26	-26	0	5	-1	3	-1	2	-2	-2	-8
PRTG	-1	-6	-19	-20	-13	-1	-6	-8	-7	-3	-4	-1	3	6	0	2	2	2	0	1	0
SERPINA9	-1	-3	-15	-8	10	43	-7	-11	-4	2	0	3	1	5	-1	1	2	9	10	7	9
TNFRSF10A	0	-2	-11	0	31	108	-7	-11	1	11	3	10	0	9	-2	0	2	5	0	2	5
TNFSF13B	-4	-7	-20	-10	19	108	-10	-14	-12	0	-6	1	1	7	1	3	2	3	-1	3	-1
VCAN	-3	-3	-10	-1	23	72	-6	-11	-1	9	0	7	0	4	-2	2	1	5	2	4	7

Green shading: %CV within ±20%. Red shading: %CV < -20% or >20%.

Qureshi et al **Biomarker Analytical Validation Manuscript** Proteomics Clin Appl

TABLE S5 Storage, processing, and stability of the MSDA Test during various

	Freeze-thaw cycle													
Analyte	Cycle 1	Cycle 2	Cycle 3	Cycle 4	Cycle 5									
APLP1	-6	6	-13	-5	-7									
CCL20	-7	-2	-13	-10	-11									
CD6	-1	0	-9	-8	-7									
CDCP1	-1	-1	-11	-8	-7									
CNTN2	1	3	-6	-1	-3									
COL4A1	2	3	-11	-5	-7									
CXCL13	-1	-5	-11	-10	-9									
CXCL9	-1	1	-11	-5	-7									
FLRT2	-2	-3	-10	-10	-8									
GFAP	-9	-4	-20	-23	-28									
GH	-7	1	-12	-15	-13									
IL-12β	-4	0	-13	-7	-9									
MOG	-3	1	-11	-7	-9									
NfL	1	-2	-12	-12	-1									
OPG	-1	-3	-11	-6	-8									
OPN	-3	-2	-11	-7	-9									
PRTG	-3	-1	-10	-9	-8									
SERPINA9	13	-2	-13	-11	-12									
TNFRSF10	-8	2	-12	-8	-9									
Α														
TNFSF13B	-1	0	-9	-4	-7									
VCAN	-1	1	-8	-4	-6									

freeze-thaw cycles for individual biomarkers

Green shading: average % difference within $\pm 20\%$. Red shading: average % difference < -20%.

Qureshi et alBiomarker Analytical Validation ManuscriptProteomics Clin Appl

TABLE S6 Initial study of the storage, processing, and stability of the MSDA Test at various temperatures (room temperature, 4°C, and -20°C) over time

and during freeze-thaw at the Disease Activity score level

Sample	-80°		R	oom te	mperati	ure		-80°		4°C					-80°	-20 C Sample					Sample	Freeze-thaw					
ID	С	4 h	Day	Day	Day	Day	Day	С	4 h	Day	Day	Day	Day	Day	С	Day	Day	Day	Day	Day	ID	Fresh	1	2	3	4	5
			1	3	7	14	28			1	3	7	14	28		1	3	7	14	28							
A	3	3	3	3	3	3	2.5	3	3.5	2.5	3	3.5	3.5	3	3	2.5	3	3.5	2.5	2.5	E	5	5.5	5	5	4	5.5
В	4	4.5	4.5	4.5	4.5	4.5	3.5	4	4	5	4.5	4.5	5	5	4	4.5	4.5	4.5	5	5	F	6.5	7	6.5	7	6.5	7
С	7	6.5	6	7	7	6.5	6.5	7	7	7.5	7	7	7.5	7	7	6	6.5	7	6.5	7	G	3	3.5	3	3.5	3.5	3.5
D	9	8.5	8.5	9	9	9	8.5	9	9	8.5	9	9	9	9	9	8.5	9	9	8.5	8.5	Н	2.5	3	2.5	2.5	2.5	3

Low (1.0-4.0) Disease Activity scores are noted in green, moderate (4.5-7.0) Disease Activity scores are noted in blue, and high (7.5-10.0) Disease Activity scores are noted in orange.

Qureshi et al **Biomarker Analytical Validation Manuscript** Proteomics Clin Appl

TABLE S7 Follow-up study of the storage, processing, and stability of the MSDA

Sample ID	-80°C	4°C			
-		Day 1	Day 2	Day 3	Day 7
А	8.5	8.5	8.5	8.5	8.5
В	5	4.5	4.5	4.5	4.5
С	7.5	6	7.5	7.5	7
D	6.5	6.5	6.5	5.5	7
E	5	5	5	5	5.5
F	7	7	7	6.5	7.5
G	5.5	5	5	5	5.5
Н	6.5	6.5	7.5	7.5	7.5
I	6	6	6.5	6	7
J	3.5	3.5	3	3.5	3
K	1.5	1	1.5	1.5	1.5
L	2.5	2.5	2.5	2.5	2
М	2.5	2.5	3	2	3
N	7.5	7.5	8.5	8	8

Test at 4°C over time at the Disease Activity score level

Low (1.0-4.0) Disease Activity scores are noted in green, moderate (4.5-7.0) Disease Activity scores are noted in blue, and

high (7.5–10.0) Disease Activity scores are noted in orange.

All rights reserved. No reuse allowed without permission. Qureshi et al **Biomarker Analytical Validation Manuscript** Proteomics Clin Appl FIGURE S1. Overview of PEA technology and MSDA Test format. Eighteen antibody pairs, labeled with DNA oligonucleotides, bind to target antigen in solution. Oligonucleotides that are brought into proximity will hybridize and are extended by a DNA polymerase. This newly created piece of DNA barcode is amplified by PCR. The amount of each DNA barcode is guantified by microfluidic gPCR (Biomark[™] HD, Fluidigm, Maryland Heights, MO, USA), with results reported in cycle threshold values. Data processing is then performed in the Olink[®] NPX Manager (Olink Proteomics, Uppsala, Sweden) software to convert the Ct values to a Normalized Protein eXpression value. The signal obtained from the assay (Normalized Protein eXpression) is converted to absolute concentration (pg/mL) using three calibrators that cover the range of sample response in the MS population (calibrators: high, middle, low) and then referenced back to the standard curve. These concentrations are then used as inputs into algorithms corresponding to disease activity and biological pathway scores.



Octave Disease Activity Test Proteomic Analysis

Biomarker Analytical Validation Manuscript

Proteomics Clin Appl

FIGURE S2. Assay interference using common drugs.

Qureshi et al



Qureshi et al

Biomarker Analytical Validation Manuscript

Proteomics Clin Appl

FIGURE S3. Assay interference using routine endogenous interferents and

heterophilic antibodies.



FIGURE S4. Percent difference of the observed protein concentration relative to the average concentration as determined from six time points (days 1, 2, 3, 4, 5, and 12) in eight samples assayed in the MSDA Test.



Biomarker Analytical Validation Manuscript

Proteomics Clin Appl

REFERENCES

Qureshi et al

- [1] Raschka, S. (2018). MLxtend: providing machine learning and data science utilities and extensions to Python's scientific computing stack. J Open Source Softw, 3, 638.
- [2] Pedregosa, F., Varoguaux, G., Gramfort, A., Michel, V., Thirion, B., Grisel, O., ... Duchesnay, E. (2011). Scikit-learn: Machine learning in Python. Journal of Machine Learning Research, 12, 2825–2830.
- [3] Chitnis, T., Foley, J., Ionete, C., El Ayoubi, N., Saxena, S., Gaitan-Walsh, P., ... Khoury, S. J. Clinical validation study results of a multivariate proteomic serum based assay for disease activity assessments in multiple sclerosis. Presented at: 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); October 13-15, 2021; Virtual.
- [4] Seabold, S., Perktold, J. (2010). Statsmodels: Econometric and statistical modeling with Python. Proceedings of the 9th Python in Science Conference, 92-96.